Your search returned 13 results.

Results
	1.	Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al. [electronic resource] by Baron, Michelle A Producer: 20040713 In: Diabetes care vol. 26 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. [electronic resource] by Israel, Marc K Istvan, Eva Baron, Michelle A Producer: 20090423 In: Vascular health and risk management vol. 4 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes. [electronic resource] by Henry, Robert R Logan, Douglas Alessi, Thomas Baron, Michelle A Producer: 20131230 In: Clinical therapeutics vol. 35 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors. [electronic resource] by Blonde, Lawrence Baron, Michelle A Zhou, Rong Banerji, Mary Ann Producer: 20140908 In: Postgraduate medicine vol. 126 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents. [electronic resource] by Banerji, Mary Ann Baron, Michelle A Gao, Ling Blonde, Lawrence Producer: 20140908 In: Postgraduate medicine vol. 126 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. [electronic resource] by Rosenstock, Julio Baron, Michelle A Dejager, Sylvie Mills, David Schweizer, Anja Producer: 20070614 In: Diabetes care vol. 30 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. [electronic resource] by Gerich, John Raskin, Philip Jean-Louis, Lisa Purkayastha, Das Baron, Michelle A Producer: 20051107 In: Diabetes care vol. 28 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes. [electronic resource] by Horton, Edward S Foley, James E Shen, Sharon G Baron, Michelle A Producer: 20040921 In: Current medical research and opinion vol. 20 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. [electronic resource] by Henry, Robert R Rosenstock, Julio Logan, Douglas Alessi, Thomas Luskey, Kenneth Baron, Michelle A Producer: 20150209 In: Journal of diabetes and its complications vol. 28 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	10.	Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA [electronic resource] by Henry, Robert R Rosenstock, Julio Denham, Douglas S Prabhakar, Prakash Kjems, Lise Baron, Michelle A Producer: 20180723 In: Diabetes care vol. 41 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	11.	Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. [electronic resource] by Rosenstock, Julio Buse, John B Azeem, Rehan Prabhakar, Prakash Kjems, Lise Huang, Holly Baron, Michelle A Producer: 20180717 In: Diabetes care vol. 41 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	12.	Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. [electronic resource] by Henry, Robert R Rosenstock, Julio Logan, Douglas K Alessi, Thomas R Luskey, Kenneth Baron, Michelle A Producer: 20140421 In: Diabetes care vol. 36 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	13.	Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. [electronic resource] by Rosenstock, Julio Foley, James E Rendell, Marc Landin-Olsson, Mona Holst, Jens J Deacon, Carolyn F Rochotte, Erika Baron, Michelle A Producer: 20080116 In: Diabetes care vol. 31 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)